SonoProbe®

High Intensity Contact Ultrasound Interstitial Medical Device

Clinical Indications targeted by the SonoProbe

Given the neurosurgical specialty of Pr. Carpentier, the SonoProbe was designed to be used for the treatment of a range of indications in the brain: tumors, epileptic lesions, radiosurgery resistant metastases, meningiomas … with a net annual incidence in Europe and in the United States of more than 400,000 patients.

Due to its design, the SonoProbe can also be adapted for the treatment of diseases in other organs. It potentially can also be used for treatments in moving organs or in organs hidden by bony structures (liver, lung …)

Below, the two main stages of treatment of a brain tumor by the SonoProbe are described.

 

The SonoProbe treatment

The first step is diagnostic. It begins with local anesthesia and stereotactic insertion of the probe within the tumor. A biopsy is performed to determine the precise histological status of the tumor. In the same step, still under local anesthesia, the treatment can take place.

 

 

 

 

The second step is therapeutic. It happens within the MRI scanner. After verification by MRI of the exact positioning of the probe relative to the tumor, treatment planning is performed. The treatment can then begin, with continuous monitoring using MR images acquired in real-time. The treatment itself lasts between 5 and 15 minutes. At the end of the procedure, the patient is discharged from the MRI, the probe is removed, and the patient is able to leave the hospital (the same day).

111

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.